Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial

被引：7
|
作者：
Fjorden, Karin [1 ]
Ekberg, Sara [2 ]
Kuric, Nevzeta [3 ]
Smedby, Karin E. [4 ,5 ]
Lagerlof, Ingemar [6 ]
Larsen, Thomas S. [7 ]
Jorgensen, Judit M. [8 ]
de Nully Brown, Peter [9 ]
Jerkeman, Mats [1 ]
机构：
[1] Lund Univ, Skane Univ Hosp, Dept Oncol, Lund, Sweden
[2] Karolinska Inst, Dept Med Solna, Div Clin Epidemiol, Stockholm, Sweden
[3] Halmstad Cty Hosp, Dept Hematol, Halmstad, Sweden
[4] Karolinska Inst, Div Hematol, Dept Med Solna, Stockholm, Sweden
[5] Karolinska Univ Hosp, Stockholm, Sweden
[6] Linkoping Univ, Dept Med & Hlth Sci, Div Drug Res, Linkoping, Sweden
[7] Odense Univ Hosp, Dept Haematol, Odense, Denmark
[8] Aarhus Univ Hosp, Dept Hematol, Aarhus, Denmark
[9] Copenhagen Univ Hosp, Rigshosp, Dept Hematol, Copenhagen, Denmark
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 196卷 / 02期
关键词：
Idelalisib; relapsed; refractory DLBCL; transformed lymphoma; IBRUTINIB;
D O I：
10.1111/bjh.17792
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：437 / 440
页数：4
相关论文
共 50 条
  • [21] Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused"
    Kesireddy, Meghana
    Lunning, Matthew A.
    ONCOLOGY-NEW YORK, 2022, 36 (06): : 360 - 369
  • [22] Phylogenetic Evolution in Refractory/Relapsed Diffuse Large B-Cell Lymphoma
    Ruminy, Philippe
    Rainville, Vinciane
    Mareschal, Sylvain
    Etancelin, Pascaline
    Joly, Berangere
    Picquenot, Jean-Michel
    Bastard, Christian
    Tilly, Herve
    Jardin, Fabrice
    BLOOD, 2012, 120 (21)
  • [23] Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Harris, Leonard Jeff
    Patel, Kruti
    Martin, Michael
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 12
  • [24] Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma
    Vacirca, J. L.
    Acs, P. I.
    Shimkus, B. J.
    Rosen, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma
    Coiffier, Bertrand
    Radford, John
    Bosly, Andre
    Martinelli, Giovanni
    Barca, Gabriela
    Davies, Andrew
    Decaudin, Didier
    Gallop-Evans, Eve
    Padmanabhan-Iyer, Swaminathan
    Van Eygen, Koen
    Wu, Ka Lung
    Gupta, Ira V.
    Lin, Thomas S.
    Goldstein, Nancy
    Jewell, Roxanne C.
    Winter, Paul
    Lisby, Steen
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (03) : 334 - 342
  • [26] Phase III trial of bendamustine plus rituximab for relapsed or refractory diffuse large B-cell lymphoma in Japan
    Kiguchi, Toru
    Terui, Yasuhito
    Izutsu, Koji
    Kameoka, Yoshihiro
    Hidaka, Michihiro
    Kato, Harumi
    Matsumura, Itaru
    Kuroda, Junya
    Ishizawa, Kenichi
    Ichikawa, Satoshi
    Ando, Kiyoshi
    Ogura, Michinori
    Tobinai, Kensei
    Fukushima, Koji
    Murayama, Kayoko
    ANNALS OF ONCOLOGY, 2021, 32 : S304 - S304
  • [27] Phase 1/2 Trial of Acalabrutinib Plus Pembrolizumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 9 - 10
  • [28] A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ward, Jeffrey P.
    Thein, Jessica
    Luo, Jingqin
    Wagner-Johnston, Nina D.
    Cashen, Amanda F.
    Fehniger, Todd A.
    Bartlett, Nancy L.
    BLOOD, 2015, 126 (23)
  • [29] Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
    Salles, Gilles
    Gopal, Ajay K.
    Minnema, Monique C.
    Wakamiya, Karen
    Feng, Huaibao
    Schecter, Jordan M.
    Wang, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (05): : 275 - 284
  • [30] Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study
    Morschhauser, Franck Andre
    Cartron, Guillaume
    Thieblemont, Catherine
    Solal-Celigny, Philippe
    Haioun, Corinne
    Bouabdallah, Reda
    Feugier, Pierre
    Bouabdallah, Krimo
    Asikanius, Elina
    Lei, Guiyuan
    Wenger, Michael
    Wassner-Fritsch, Elisabeth
    Salles, Gilles Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) : 2912 - +
12345